Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma
Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively rep...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
20 September 2021
|
| In: |
Cancers
Year: 2021, Volume: 13, Issue: 18, Pages: 1-13 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers13184706 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers13184706 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/13/18/4706 
|
| Author Notes: | Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass and Nicola Giesen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1777668840 | ||
| 003 | DE-627 | ||
| 005 | 20240429212133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211117s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13184706 |2 doi | |
| 035 | |a (DE-627)1777668840 | ||
| 035 | |a (DE-599)KXP1777668840 | ||
| 035 | |a (OCoLC)1341423917 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bärtsch, Marc-Andrea |d 1988- |e VerfasserIn |0 (DE-588)1099464854 |0 (DE-627)858599074 |0 (DE-576)469306505 |4 aut | |
| 245 | 1 | 0 | |a Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma |c Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass and Nicola Giesen |
| 264 | 1 | |c 20 September 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.11.2021 | ||
| 500 | |a This article belongs to the special issue "Autologous and allogeneic stem cell transplant in cancer therapy" | ||
| 520 | |a Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57%) attained ≥ very good partial response (VGPR), which increased to 34/44 (77%) at best response after salvage HDCT/ASCT. Median progression-free survival (PFS) was 23.3 months from salvage HDCT/ASCT. Patients with ≥ VGPR at the time of salvage HDCT/ASCT and those receiving maintenance treatment post salvage HDCT/ASCT had significantly superior PFS (hazard ratio (HR) 0.19, p = 0.001 and HR 0.20, p = 0.009). In patients achieving at least an equal depth of response before salvage HDCT/ASCT as before frontline HDCT/ASCT, PFS after salvage HDCT/ASCT was comparable to the frontline situation (p = 0.3). This is the first report of state-of-the-art triplet re-induction and salvage HDCT/ASCT for RRMM after frontline transplantation. Deep remissions achieved with KRd translate into prolonged PFS following salvage HDCT/ASCT and are enhanced by maintenance treatment. | ||
| 650 | 4 | |a lenalidomide maintenance | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a salvage autologous stem cell transplantation | |
| 650 | 4 | |a salvage high-dose chemotherapy | |
| 700 | 1 | |a Fougereau, Mathilde |d 1995- |e VerfasserIn |0 (DE-588)1327910527 |0 (DE-627)1887384928 |4 aut | |
| 700 | 1 | |a Hielscher, Thomas |e VerfasserIn |0 (DE-588)1159594791 |0 (DE-627)1022977768 |0 (DE-576)50506068X |4 aut | |
| 700 | 1 | |a Sauer, Sandra |d 1975- |e VerfasserIn |0 (DE-588)1060031140 |0 (DE-627)799171778 |0 (DE-576)416132855 |4 aut | |
| 700 | 1 | |a Breitkreutz, Iris |d 1970- |e VerfasserIn |0 (DE-588)124783309 |0 (DE-627)366051806 |0 (DE-576)186798725 |4 aut | |
| 700 | 1 | |a Jordan, Karin |d 1974- |e VerfasserIn |0 (DE-588)123243327 |0 (DE-627)706224078 |0 (DE-576)293619174 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 700 | 1 | |a Hillengaß, Jens |d 1974- |e VerfasserIn |0 (DE-588)124918549 |0 (DE-627)368073823 |0 (DE-576)294568298 |4 aut | |
| 700 | 1 | |a Giesen, Nicola |d 1983- |e VerfasserIn |0 (DE-588)141844272 |0 (DE-627)631828524 |0 (DE-576)32643657X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 13(2021), 18, special issue, Artikel-ID 4706, Seite 1-13 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:18 |g supplement:special issue |g elocationid:4706 |g pages:1-13 |g extent:13 |a Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers13184706 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/13/18/4706 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211117 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 141844272 |a Giesen, Nicola |m 141844272:Giesen, Nicola |d 910000 |d 910100 |e 910000PG141844272 |e 910100PG141844272 |k 0/910000/ |k 1/910000/910100/ |p 11 |y j | ||
| 998 | |g 124918549 |a Hillengaß, Jens |m 124918549:Hillengaß, Jens |d 50000 |e 50000PH124918549 |k 0/50000/ |p 10 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 123243327 |a Jordan, Karin |m 123243327:Jordan, Karin |d 910000 |d 910100 |e 910000PJ123243327 |e 910100PJ123243327 |k 0/910000/ |k 1/910000/910100/ |p 6 | ||
| 998 | |g 124783309 |a Breitkreutz, Iris |m 124783309:Breitkreutz, Iris |d 50000 |e 50000PB124783309 |k 0/50000/ |p 5 | ||
| 998 | |g 1060031140 |a Sauer, Sandra |m 1060031140:Sauer, Sandra |d 910000 |d 910100 |e 910000PS1060031140 |e 910100PS1060031140 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1159594791 |a Hielscher, Thomas |m 1159594791:Hielscher, Thomas |d 140000 |e 140000PH1159594791 |k 0/140000/ |p 3 | ||
| 998 | |g 1327910527 |a Fougereau, Mathilde |m 1327910527:Fougereau, Mathilde |d 60000 |e 60000PF1327910527 |k 0/60000/ |p 2 | ||
| 998 | |g 1099464854 |a Bärtsch, Marc-Andrea |m 1099464854:Bärtsch, Marc-Andrea |d 910000 |d 910100 |e 910000PB1099464854 |e 910100PB1099464854 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1777668840 |e 4002789195 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1777668840"],"doi":["10.3390/cancers13184706"]},"recId":"1777668840","origin":[{"dateIssuedDisp":"20 September 2021","dateIssuedKey":"2021"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Bärtsch, Marc-Andrea","family":"Bärtsch","role":"aut","given":"Marc-Andrea"},{"given":"Mathilde","role":"aut","family":"Fougereau","display":"Fougereau, Mathilde"},{"given":"Thomas","family":"Hielscher","display":"Hielscher, Thomas","role":"aut"},{"given":"Sandra","role":"aut","display":"Sauer, Sandra","family":"Sauer"},{"family":"Breitkreutz","display":"Breitkreutz, Iris","role":"aut","given":"Iris"},{"given":"Karin","role":"aut","display":"Jordan, Karin","family":"Jordan"},{"display":"Müller-Tidow, Carsten","family":"Müller-Tidow","role":"aut","given":"Carsten"},{"given":"Hartmut","role":"aut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"role":"aut","family":"Raab","display":"Raab, Marc-Steffen","given":"Marc-Steffen"},{"given":"Jens","role":"aut","family":"Hillengaß","display":"Hillengaß, Jens"},{"given":"Nicola","family":"Giesen","display":"Giesen, Nicola","role":"aut"}],"relHost":[{"pubHistory":["1.2009 -"],"disp":"Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myelomaCancers","part":{"pages":"1-13","volume":"13","text":"13(2021), 18, special issue, Artikel-ID 4706, Seite 1-13","year":"2021","extent":"13","issue":"18"},"recId":"614095670","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Cancers","title":"Cancers"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"note":["Gesehen am 27.05.2020"],"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"origin":[{"dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisherPlace":"Basel","publisher":"MDPI"}],"id":{"issn":["2072-6694"],"eki":["614095670"],"zdb":["2527080-1"]}}],"physDesc":[{"extent":"13 S."}],"title":[{"title_sort":"Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma","title":"Carfilzomib, lenalidomide, and dexamethasone followed by salvage autologous stem cell transplant with or without maintenance for relapsed or refractory multiple myeloma"}],"language":["eng"],"name":{"displayForm":["Marc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, Sandra Sauer, Iris Breitkreutz, Karin Jordan, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc-Steffen Raab, Jens Hillengass and Nicola Giesen"]},"note":["Gesehen am 17.11.2021","This article belongs to the special issue \"Autologous and allogeneic stem cell transplant in cancer therapy\""]} | ||
| SRT | |a BAERTSCHMACARFILZOMI2020 | ||